Clin Infect Dis. 1994 Oct;19(4):687-92. Unique Identifier : AIDSLINE
We report the course of oropharyngeal infection by Candida albicans that
was refractory to treatment with fluconazole in two patients infected by
the human immunodeficiency virus (HIV). We also review the epidemiology
of C. albicans with decreased in vitro and in vivo susceptibility to
azole antifungal agents, the significance of such isolates, the known
mechanisms by which C. albicans may become less susceptible to azole
antifungal agents, and the efficacy of various treatments for mucosal
candidiasis. The occurrence in HIV-infected patients of mucosal
candidiasis that is refractory to therapy with fluconazole and is due to
C. albicans that demonstrates decreased in vitro susceptibility to
fluconazole has been reported since 1990. Following the release of
miconazole and ketoconazole in the late 1970s, C. albicans with
decreased in vitro susceptibility to these agents was isolated from
patients with chronic mucocutaneous candidiasis who required repeated
and prolonged courses of therapy. Subsequently, C. albicans with
decreased in vitro-susceptibility to ketoconazole, clotrimazole, and
itraconazole has been isolated from HIV-infected patients. Recent
reports of the sexual and nosocomial transmission of wild-type C.
albicans indicate the possibility of future person-to-person
transmission of C. albicans with decreased in vitro susceptibility to
azole antifungal agents.
Adult Amphotericin B/PHARMACOLOGY AIDS-Related Opportunistic
Infections/*DRUG THERAPY Candida albicans/*DRUG EFFECTS Candidiasis,
Oral/*DRUG THERAPY Case Report Drug Resistance, Microbial
Fluconazole/*PHARMACOLOGY Human Itraconazole/PHARMACOLOGY Male
Microbial Sensitivity Tests Middle Age JOURNAL ARTICLE